🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Alzheimer's Disease
Clinical trial register · United States · industry-sponsored

Alzheimer's Disease Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
Florida 16 California 10 Georgia 6 Massachusetts 6 Illinois 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Bristol-Myers Squibb4 GlaxoSmithKline2 Eli Lilly and Company2 Eisai Inc.2 T3D Therapeutics, Inc.1
State
Florida16 California10 Georgia6 Massachusetts6 Illinois5
All 30 states
Target enrolment
to
22 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411Alzheimer's Disease
Hoffmann-La Roche
Phase 3
1,600
California, Florida, New York
2026-11-30
Not yet open
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
NCT06964230Alzheimer's Disease
T3D Therapeutics, Inc.
Phase 2/3
376
North Carolina
2026-10-26
Recruiting
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
NCT07764146Alzheimer s Disease
Voyager Therapeutics
Phase 1
18
Florida
2026-09-03
Not yet open
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
NCT07780383Alzheimer's Disease, Healthy Participants
Bristol-Myers Squibb
Phase 1
84
California
2026-08-21
Recruiting
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213Dementia, Alzheimer's Type, Alzheimer's Disease
Sanofi
Phase 2
160
Florida
2026-07-28
Recruiting
Crownlands Observing Progression With Neurons Study
NCT07611396Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Crownlands
Observational
160
Maryland
2026-05-19
Recruiting
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
NCT07599670Alzheimer's Disease
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Recruiting
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709Alzheimer's Disease
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
Novartis Pharmaceuticals
Phase 2
407
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
Bristol-Myers Squibb
Phase 3
586
California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan, Mississippi
2025-07-21
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745Alzheimer's Disease
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Recruiting
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
NCT07821658Alzheimer's Disease
Eisai Inc.
Observational
6,700
New Jersey
2025-05-23
Recruiting
Pulsed Electromagnetic Field Treatment With Dementia Patients
NCT06862557Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Herrick Medical LLC
Not applicable
48
Florida
2025-04-01
Recruiting
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
NCT06810960Alzheimer's Disease
Eisai Korea Inc.
Observational
3,000
New Jersey
2025-02-24
Recruiting
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
NCT07701161Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
Neurogen Biomarking LLC
Observational
1,000
Illinois, Michigan, North Carolina
2025-01-13
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Active, closed
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258Alzheimer's Disease
Eisai Inc.
Phase 2
105
Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee
2024-09-30
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
GAP Innovations, PBC
Observational
1,200
Florida, Illinois, Michigan, Nevada, New York, Ohio, Pennsylvania, Rhode Island
2024-09-26
Active, closed
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
NCT06079190Alzheimer's Disease
GlaxoSmithKline
Phase 2
367
California, Florida, Georgia, Illinois, Missouri, New Jersey, New York, North Carolina
2023-10-20
Active, closed
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
NCT06043700Alzheimer's Disease
Eisai Limited
Observational
2,000
Florida, Maryland
2023-09-12
Active, closed
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,175
Arizona, California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Rhode Island
2023-02-28
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/alzheimer-s-disease

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.